What's in SynAct Pharma Aps's pipeline?

SynAct Pharma Aps has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with SynAct Pharma Aps's portfolio?

Top competitors by shared drug class: Adocia, Cambridge University Hospitals NHS Foundation Trust, Eli Lilly and Company, Hospices Civils de Lyon, Steno Diabetes Center Copenhagen.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/synact-pharma-aps.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

SynAct Pharma Aps — Portfolio Competitive Intelligence Brief

SynAct Pharma Aps pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Adocia · 1 shared drug class
Cambridge University Hospitals NHS Foundation Trust · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Hospices Civils de Lyon · 1 shared drug class
Steno Diabetes Center Copenhagen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for SynAct Pharma Aps:

Cite this brief

Drug Landscape (2026). SynAct Pharma Aps — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/synact-pharma-aps. Accessed 2026-05-13.